**Objective:** Tumor growth is one of the most lethal attributes of human malignancy. The expression of CCDC7, a novel gene which has multiple functions, has been shown to be associated with tumor growth and poor prognosis in patients with cancer. However, the specific functions of CCDC7 remain unclear. Here, we investigated the molecular mechanisms underlying the effects of CCDC7 on proliferation in cervical cancer.

**Materials and Methods:** The MTT and EdU assays were performed to evaluate the function of CCDC7. The immunohistochemical, quantitative real-time PCR (qRT-PCR), ELISA and Western blot assay were used to detect the gene and protein expression in tissues and cells. A xenograft test was conducted to detect the impact of CCDC7 on tumor development in vivo.

**Results:** In immunohistochemical analysis of 193 cases, normal cervical tissue and cervical cancer tissue show that CCDC7 expression is closely correlated with the development of cervical cancer and was positively correlated with the clinical stage and histological grade. Overexpression or knockdown of CCDC7 affected cell proliferation in cervical cancer cells in vitro. In a nude mouse xenograft model in vivo, knockdown of CCDC7 inhibited cell proliferation and tumor growth. Furthermore, CCDC7 overexpression upregulated interleukin (IL)-6 and vascular endothelial growth factor (VEGF) at mRNA and protein levels, and treatment with recombinant IL-6 or VEGF proteins also increased CCDC7 expression. In a case set of 80 patients with cervical cancer, we found that CCDC7, IL-6, and VEGF affected patient prognosis. Finally, inhibition of various signaling pathways using specific inhibitors indicated that CCDC7 blocked the decrease in cell proliferation observed following suppression of the JAK-STAT3 pathway, suggesting that CCDC7 functioned via this critical signaling network.

**Conclusion:** These findings indicated that CCDC7 may be a novel target for the treatment of cervical cancer and may have applications as a predictive marker for tumor growth in cervical carcinoma.

**Keywords:** CCDC7, IL-6, VEGF, tumor growth, cervical cancer, gene therapy
space involvement are associated with prognosis in patients with cervical cancer. Therefore, investigation of tumor growth-related regulatory molecules, molecular targets, and treatments for tumor growth in cervical cancer is necessary and may facilitate the development of novel therapies to improve survival in patients with cervical cancer. Hence, many researchers have been carrying out studies aimed at identifying novel predictors or therapeutic targets for cervical carcinoma.

The coiled-coil domain containing 7 (CCDC7) gene (Gene ID: 221016) encodes a protein with unknown functions. And it is the longest transcript of the CCDC7 gene family. Our previous studies have shown that members of this gene family play an important role in tumorigenesis, and may serve as the potential targets for biotherapy. In clinical studies by real-time PCR experiments, we found that the mRNA expression level of members of CCDC7 gene family is higher in cancer tissues than the adjacent tissues in the contexts of cervical cancer, endometrial cancer, and colorectal cancer. Moreover, the mRNA expression level of members of CCDC7 gene family is significantly increased with more advanced tumor stage in clinical specimens from patients with colorectal cancer. Members of CCDC7 gene family exhibit higher expression in patients with early colorectal cancer, which is associated with a particularly poor prognosis. However, while it is clear that expression of the CCDC7 protein is associated with tumorigenesis, the function of CCDC7 and the mechanisms through which CCDC7 affects tumor growth are not clear.

Interleukin-6 (IL-6) is an important regulator of immune and inflammatory responses and functions as a growth factor for many types of tumor cells. IL-6 is a pleiotropic cytokine involved in tumor initiation, promotion, and progression and has been shown to play a central role in cancer-associated inflammation and the regulation of tumor growth. One of the functions of this multifunctional cytokine is to activate target genes involved in cell proliferation. Moreover, IL-6 has been reported to be indispensable for oncogene-induced cell transformation and tumorigenesis, indicating the importance of IL-6 in tumor initiation. Several studies examining IL-6 expression in human gastric cancer tissues have shown that IL-6 expression is positively correlated with VEGF expression. However, the specific role of IL-6 in cervical cancer has not yet been clarified.

The IL-6 and Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway is activated in a variety of human cancers; the JAK-STAT3 pathway is an important oncogenic signaling cascade that consists of the JAK family of non-receptor tyrosine kinases and the STAT family of transcription factors. Persistent JAK-STAT3 signaling is implicated in many biological processes. STAT3 is known to be involved in both tumor-intrinsic and tumor-extrinsic processes, supporting tumor survival and metastasis. However, in most malignancies, STAT proteins, in particular STAT3, is aberrantly activated (tyrosine phosphorylation) in the majority of cancers. Importantly, the JAK-STAT3 signaling pathway has been regarded as a critical regulator of tumorigenesis, and the intensity of STAT3 activation within the tumor stroma is a major determinant of cytokine responses and cellular functions promoting tumor growth. Binding of cell surface receptors with ligands, such as IL-6, induces tyrosine phosphorylation of STAT3 protein by JAK and growth factor receptor tyrosine kinases. Thus, abnormalities in the JAK/STAT signaling pathway are thought to be involved in the oncogenesis of several types of cancers.

In this study, we aimed to elucidate the role of CCDC7 in promoting the tumorigenesis of cervical cancer using cell culture, mouse models, and clinical specimens.

Materials and Methods

Materials
The recombinant human proteins VEGF and IL-6 were purchased from Pepro Tech (Suzhou, China). Anti-STAT3 (1:1000), anti-JAK (1:1000), anti-phospho-STAT3 (Y705) (1:1000), and anti-phospho-JAK (Y1007/1008) (1:1000) antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). The anti-CCDC7 (1:1000) antibody was purchased from Abcam (Cambridge, UK). Mouse anti-PCNA (1:1000) was obtained from BOSTER (China). The secondary antibody (goat anti-rabbit IgG) was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). TransIT®-2020 Transfection Reagent was purchased from Mirus (USA). The total RNA kit was purchased from Tian Gen (China), and the first-strand cDNA synthesis kit and SYBR Premix Ex Taq were purchased from TaKaRa (Shiga, Japan). The ELISA kits for IL-6 and VEGF were from DAKEWE (China). Tumor microarrays were purchased from Alenabio (Shanxi, China). All other kits or reagents were purchased from the Beyotime Institute of Biotechnology (Shanghai, China). The recombinant plasmid CCDC7-shRNA was obtained from Genechem.
The plasmid was prepared using an Endofree Plasmid Giga kit purchased from Qiagen (Chatsworth, CA, USA).

**Cell Culture**

**Transient Transfections**

HeLa cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 10 mM l-Glu, and 5 mg/mL penicillin/streptomycin at 37 °C and in a humidified incubator containing 5% CO₂.

HeLa cells were seeded in 6-well plates at a density of 1 × 10⁵ cells/well. Twenty-four hours later, 2.5 mL complete growth medium was added per well. Transfections were carried out using 250 μL of reduced-serum medium with 2.5 μg CCDC7 or siCCDC7 according to the protocol for the TransIT-2020 reagent. Cells were incubated for 24–48 h before use.

**MTT Assay**

Cell proliferation was evaluated by MTT assay (Sigma, St. Louis, MO, USA). Cells were seeded at a density of 3 × 10³ or 5 × 10³ cells per well in 96-well plates (n = 6 wells per treatment) in DMEM containing 10% FCS in a final volume of 100 μL. Twenty-four hours later, cells were transected with CCDC7 or siCCDC7 as previously described. After transfection, cells were incubated in the presence of MTT (20 μL/well of a 5 g/L solution in sterile phosphate-buffered saline [PBS]) for 4 h at 37 °C. The medium was removed, and 150 μL of dimethylsulfoxide (DMSO) was used to dissolve the MTT formazan crystals. The absorbance from each well was measured at 570 nm using a microplate reader (Multiskan MK3, Thermo Labsystems, Finland).

**EdU Cell Proliferation Assay**

HeLa cells (1 × 10⁵ cells/well) were seeded in 24-well plates (n = 3 wells per treatment) and then transfected 24 h later with CCDC7 or siCCDC7. EdU assays were then carried out according to the manufacturer’s protocol. Cells were imaged under an inverted fluorescence microscope.

**Quantification of CCDC7, IL-6, and VEGF mRNA by qRT-PCR**

Total RNA was extracted from the transfected cells with an RNA Simple Total RNA kit according to the manufacturer’s instructions. Next, 1 μg of RNA was used to synthesize cDNA using a first-strand cDNA synthesis kit. qRT-PCR analysis was performed using SYBR Premix Ex Taq according to the manufacturer’s protocol. Data were normalized according to the level of β-actin expression in each sample. For real-time PCR, a commercial power SYBR Green PCR master mix was used. Briefly, 1 μg of total RNA was used as the template and then reverse-transcribed using an oligo primer. The cDNA was further amplified in the qPCR assay using a universal reverse primer and a specific forward primer (Table S4). The reaction solution consisted of 2.0 μL diluted RT-PCR product and 0.5 μM of each paired primer. The PCR protocol included initial denaturation at 95 °C for 1 min and then 39 cycles of 95 °C for 5 s, 59 °C (60 °C) for 20 s, and 65°C for 5 s, and a final step at 95 °C followed by melting curve analysis. The absolute mRNA levels in each sample were calculated according to a standard curve created using serial dilutions of known amounts of specific templates against corresponding cycle threshold (Ct) values. Each sample was tested in triplicate. Cycle threshold (Ct) values were obtained graphically for IL-6, CCDC7, VEGF, and β-actin. The difference in Ct values between β-actin and IL-6, CCDC7, VEGF are presented as ΔCt values.

**Quantification of IL-6 and VEGF Secretion by ELISA**

HeLa cells (1 × 10⁵ cells/well) were seeded in 6-well plates. Twenty-four hours later, the cells were transfected with CCDC7 or siCCDC7. After incubation, the culture supernatants were collected, and the levels of IL-6 and VEGF were analyzed by human IL-6 and VEGF ELISA kits according to the manufacturer’s protocol. The results were adjusted according to the total number of cells. Each sample was tested in triplicate.

**Western Blotting**

All protein samples for Western blot analysis were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 12% gels and then transferred to nitrocellulose membranes. The membranes were then blocked for 1 h at room temperature in Tris-buffered saline (TBS) containing 0.1% Tween 20 and 5% fat-free milk. All primary antibody incubations were performed for 18 h at 4 °C. Secondary antibody incubations were carried out at room temperature for 1 h. Secondary antibodies conjugated with horseradish peroxidase (HRP) were used for detection by
enhanced chemiluminescence (SuperSignal; Pierce, Rockford, IL, USA) or ECL Plus (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the manufacturer’s instructions.

Immunohistochemical Staining
Tissues were dewaxed, and antigens were retrieved using high pressure. Then, the activity of endogenous peroxidases was blocked using 3% hydrogen peroxide for 10 min. After immersion in normal goat serum for 30 min, tissues were subjected to primary antibody incubation at 4 °C overnight. Subsequently, sections were washed with PBS and incubated with secondary antibodies that had been labeled with biotin for 30 min at 37 °C. After washing, the sections were incubated with the HRP complex for 30 min at 37 °C and visualized using diaminobenzidine (DAB).

All immunohistochemical images were obtained using an Olympus BX51 microscope equipped with a 40× objective lens (Olympus) and a DP 50 camera (Olympus). Images were processed using DPC controller software (Olympus).

The immunohistochemical staining was evaluated using a semiquantitative scoring method. The total CCDC7, IL-6, and VEGF staining was scored as per staining intensity: no staining (0), light positive staining (1), medium positive staining (2), and strong positive staining (3). The positively stained area was scored as: < 5% (0), 5%–25% (1), 26%–50% (2), 51%–75% (3), and > 75% (4). A final score was calculated by multiplying the intensity score by the expression score and the rating (from 0 to 12) was determined for each case.

Animal Studies
Four- to six-week-old nude BALB/c female mice were obtained from HFK Bioscience (Beijing, China) and maintained at the Sichuan University, Chengdu. Animals were inoculated subcutaneously (s.c.) with a total of 100 μL containing 1 × 10^7 HeLa cells into the right shoulder. The interval between the first and the final inoculation into the mice was less than 1 h.

When the mean diameter of the tumors reached 5 mm (5 days after inoculation), the mice were separated at random into three groups (n = 8 per group): the NS group, receiving 100 μL saline; the control-shRNA group, receiving 10 μg of the HK plasmid and 50 μg liposome complexes (final volume = 100 μL); and the CCDC7-shRNA group, receiving 10 μg of the shRNA plasmid and 50 μg liposome complexes (final volume = 100 μL). Nude mice were treated once daily for 10 days via injections around the tumor.

Tumor size was monitored by measuring the largest diameter and the diameter perpendicular to the largest diameter using a caliper once every 3 days. Tumor volume was calculated according to the following formula: \( V = \text{length} \times \text{width}^2 \times 0.52. \) All of the data are represented as means ± standard errors of the means (SEMs). After 25 days of treatment, the mice were sacrificed, and tumors were isolated and fixed in 4% neutral formalin for histological analysis.

Statistical Analysis
The significance of differences between samples was determined using Student’s t-test or one-way analysis of variance (ANOVA) implemented in GraphPad Prism 5 (GraphPad, San Diego, CA, USA). Data are presented as means ± SEMs. Each experiment was performed with triplicate samples, and all experiments were repeated at least twice. Statistical significance was defined as \( P < 0.05. \)

Results
CCDC7 Expression in Cervical Tissues
In order to study the clinical significance of CCDC7 in cervical cancer tissue, we performed immunohistochemical analysis of CCDC7 expression in 193 cases of cervical tissue in a microarray (Table 1). The results showed that CCDC7 expression was significantly higher in cancer tissues than in normal cervical tissues. Indeed, while CCDC7 expression in normal cervical tissues was negative or weakly positive (Figure 1A), significantly increased expression was observed with increasing grade and pathological stage of cervical cancer (Figure 1B and C). Thus, CCDC7 may be involved in regulating the growth of cervical cancer.

Overexpression of CCDC7 Promoted the Proliferation of HeLa Cells in vitro
To investigate the function of CCDC7 in cervical cancer cells, we transfected HeLa cells with CCDC7. As shown using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR), the expression of CCDC7 increased eight-fold when compared with that in the control cells after 24, 36, and 48 h of growth (Figure S1A). To study the effects of CCDC7 on proliferation in HeLa cells, we used EdU assays to measure cell numbers and found a 62% increase in growth compared with the control (Figure 2A and B). Importantly, no differences in growth rates were observed between...
the control group and the vector-transfected cells ($P > 0.05$). Moreover, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays indicated that transfection with CCDC7 increased the proliferation of HeLa cells by 55% compared to that of the control (Figure 2C). Additionally, the expression of PCNA protein, a marker of proliferation, was increased following transfection with CCDC7 (Figure 2D). Thus, taken together, these results indicated that CCDC7 expression promoted the proliferation of HeLa cells.

**Knockdown of CCDC7 Suppressed HeLa Cell Proliferation in Vitro and Vivo**

Next, we analyzed the effects of CCDC7 knockdown via siRNA on HeLa cell proliferation using MTT and EdU assays. As shown in Figure 3, we found that cell proliferation was inhibited in a time-dependent manner in HeLa cells transfected with siRNA for 24–72 h, as compared with the negative control group (Figure S1B). The EdU assay detected that the cell proliferation rate decreased to 55.27% (Figure 3A and B) and the inhibition rate was
To further assess the function of CCDC7, we also examined the expression of PCNA. As expected, PCNA expression decreased following transfection with siRNA for CCDC7 (Figure 3D). These findings suggested that knockdown of CCDC7 inhibited the growth of HeLa cells in vitro.

Because of these dramatic effects of CCDC7 knockdown in cells, we next used a mouse xenograft model to investigate the effects of CCDC7 inhibition in tumors. Mice bearing HeLa-derived tumors were treated daily with normal saline, Lip-Control-shRNA, or Lip-CCDC7-shRNA, and tumor size was analyzed. Importantly, tumors in the CCDC7-shRNA group were significantly smaller than those in the control group after 2 (Figure 4A) and 10 (Figure 4B) days of treatment. Moreover, animals treated with Lip-CCDC7-shRNA showed a significant decrease in the average tumor volume when compared with the controls \((p < 0.05; \text{Figure } 4C)\). Tumor wet weights were also reduced after 30 days \((0.76 \pm 0.041 \text{ and } 0.64 \pm 0.031 \text{ g in the control and vector groups, respectively, versus } 0.34 \pm 0.025 \text{ g in the CCDC7-sh group; Figure } 4D; p < 0.0001)\). Thus, these data supported that knockdown of CCDC7 by RNA interference suppressed the proliferation and oncogenic potential of cervical cancer cells and decreased tumor formation in nude mouse xenografts.

### IL-6 and VEGF Were Upregulated Following Overexpression of CCDC7

Next, because IL-6 and VEGF are important cytokines involved in a variety of cancer-related phenotypes, we examined the effects of CCDC7 overexpression on IL-6 and VEGF in HeLa cells by qRT-PCR and enzyme-linked immunosorbent assay (ELISA). As shown in Figure 5, when compared with the negative control, CCDC7 transfection increased the expression of IL-6 and VEGF mRNA and protein. Specifically, IL-6 mRNA expression was increased by 73.86%, 80.85%, and 71.11% \((\text{Figure } 5A.a)\), and IL-6 protein expression was increased by 22.9%, 49.01%, and 48.73% \((\text{Figure } 5A.b)\) in CCDC7-transfected cells at 24, 36, and 48 h after transfection, respectively. VEGF mRNA expression was increased by 57.83%, 66.50%, and 40.38% \((\text{Figure } 5A.c)\), while VEGF protein expression was increased by 35.1%, 47.78%, and 71.37% \((\text{Figure } 5A.d)\) in CCDC7-transfected cells at 24, 36, and 48 h after transfection, respectively. These data indicated that IL-6, VEGF, and CCDC7 were all achieving the highest expression after CCDC7 transfection 48 h, moreover, they had the same consistency in dynamic expression.

### CCDC7 RNAi Significantly Inhibited IL-6 and VEGF Expression in HeLa Cells

Next, we examined whether the opposite effect could be observed, ie, whether knockdown of CCDC7 resulted in decreased expression of IL-6 and VEGF. As shown in Figure 5, when compared with the negative control group, CCDC7 siRNA transfection decreased the expression of IL-6 and VEGF mRNA and protein. Specifically, IL-6 mRNA expression was reduced by 82%, 90%, and 97% \((\text{Figure } 5B.a)\), while IL-6 protein expression was reduced by 42%, 55%, and 65%

### Table 1. Relationship Between CCDC7 Expression and Indicators of Cervical Cancer Clinical Pathology

| Factors         | Number of Patients | Average Score | \(p\) value |
|-----------------|--------------------|---------------|-------------|
| Group           |                    |               |             |
| Normal          | 29                 | 3.17 ± 0.33   | 0.001       |
| Adenocarcinoma  | 156                | 6.48 ± 0.25   |             |
| Metastatic      | 8                  | 9.50 ± 0.98   |             |
| Age             |                    |               |             |
| <60 years       | 91                 | 7.46 ± 0.63   | 0.6460      |
| ≥60 years       | 78                 | 7.15 ± 0.35   |             |
| Differentiation |                    |               |             |
| Well            | 30                 | 5.46 ± 0.68   | 0.1467      |
| Moderate        | 72                 | 7.15 ± 0.35   |             |
| Poor            | 25                 | 8.24 ± 0.53   |             |
| Clinical stage  |                    |               |             |
| I               | 45                 | 5.53 ± 0.50   | 0.001       |
| II              | 75                 | 6.22 ± 0.32   |             |
| III             | 29                 | 8.10 ± 0.58   |             |
| IV              | 7                  | 8.71 ± 1.04   |             |
| T               |                    |               |             |
| T1              | 65                 | 5.43 ± 0.43   | 0.04        |
| T2              | 55                 | 6.27 ± 0.40   |             |
| T3              | 3                  | 9.00 ± 1.73   |             |
| T4              | 2                  | 10.50 ± 1.50  |             |
| N               |                    |               |             |
| N0              | 103                | 5.21 ± 0.31   | 0.01        |
| N1              | 23                 | 7.30 ± 0.63   |             |
| M               |                    |               |             |
| M0              | 121                | 5.34 ± 0.30   | 0.01        |
| M1              | 5                  | 9.60 ± 0.97   |             |

Note: Clinical and TNM stagings were according to American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th edition.
VEGF mRNA expression was reduced by 83%, 89%, and 92% (Figure 5B.c), while VEGF protein expression was reduced by 54%, 75%, and 78% (Figure 5B.d) in CCDC7 siRNA-transfected cells at 24, 36, and 48 h after transfection, respectively. These data indicated that knockdown CCDC7 can downregulate IL-6 and VEGF. They also had the same consistency in dynamic expression.

Treatment with Recombinant IL-6 or VEGF Protein Enhanced CCDC7 Expression

IL-6 has been reported to promote VEGF-dependent angiogenesis in human cancer cells. However, little is known about the relationships among IL-6 and VEGF expression levels in cervical cancer. Therefore, we next examined the expression of CCDC7, IL-6, and VEGF after treatment of cells with recombinant VEGF proteins and IL-6 proteins.
respectively. The results showed that VEGF proteins treatment increased the expression of CCDC7 mRNA in a concentration-dependent manner, as shown in Figure 6A. On the other hand, stimulation with VEGF also upregulated IL-6 mRNA and protein expression in the Hela cells (Figure 6B, C). Moreover, that IL-6 proteins treatment increased the expression of CCDC7 mRNA in a concentration-dependent manner, as shown in Figure 6D. Interestingly, stimulation with IL-6 also increased the expression of VEGF mRNA and protein in the Hela cells (Figure 6E, F). These data suggested that IL-6 promoted VEGF and CCDC7 expression, while VEGF also promoted IL-6 and CCDC7 expression in HeLa cells.

**Expression of CCDC7, IL-6, and VEGF in Xenograft Tumors and Human Cervical Cancer Samples**

The expression levels of CCDC7, IL-6, and VEGF were next analyzed in xenograft tumors from our nude mouse model and in human cervical cancer samples. Tumor sections from the
CCDC7-shRNA group displayed significantly decreased of positive cells when compared with the NS and control-sh treatment groups ($P < 0.05$; Figure 7A). Moreover, Western blotting analysis revealed that the expression of CCDC7, IL-6, VEGF, and PCNA were significantly reduced in the CCDC7-sh group compared with the NS group (Figure 7B). To further confirm the expression patterns of CCDC7, IL-6, and VEGF in cervical cancer, we used two clinical cervical cancer samples (Figure 7C) of different clinical stages with the corresponding pericarcinoma tissues. The left one was stage 1, and the right one was stage 3. The results were similar to those observed in tumors from our xenograft model. Therefore, these data suggested that CCDC7 was clinically relevant in the context of cervical cancer.
Expression of CCDC7, VEGF, and IL-6 Was Associated with Tumor Growth

Next, we analyzed the roles of CCDC7, IL-6, and VEGF in cervical cancer using three tissue microarrays of cervical cancer specimens. Statistical analysis indicated that CCDC7, IL-6, and VEGF expression levels were significantly lower in normal cervical tissues than in squamous carcinoma tissues ($P < 0.001$; Tables S1–3). Significant differences were observed between well, moderately, and poorly differentiated carcinoma tissues; different clinical stages showed also significant differences in expression (Tables S1–3). As shown in Figure 8, levels of CCDC7, IL-6, and VEGF were also significantly different between squamous carcinoma tissues classified as stages I, II, and III, as compared with noncancerous tissues, which suggesting that the expression of CCDC7, IL-6, and VEGF was altered with tumor growth. This further supported that tumor growth was associated with CCDC7 expression in cervical carcinoma. Moreover, CCDC7, IL-6, and VEGF had the same trend in different pathological grading and clinical staging. So there may be a mechanism among the three molecules, which effect the occurrence and development of cervical cancer.

CCDC7 Regulated IL-6 and VEGF Though JAK-STAT3 Pathway

Next, we sought to examine the mechanisms through which CCDC7 may affect cervical cancer growth using an array of signaling pathway inhibitors. In our analysis, the phosphoinositol 3 kinase (PI3K), mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), MAP kinase kinase (MEK1/2), and JAK pathways were considered to have the effect of promoting cell proliferation. We found that AG490, which was the inhibition of JAK pathways was linked to the effect of CCDC7 on cell proliferation. We used MTT assay (Figure S3A) and EdU assay (Figure S2 and S3B) to measure the proliferation of HeLa cells. Compared with control groups, the cell number of the JAK group decreased to 53%, at the same time, the other pathways did not effect the proliferation of HeLa cells. After the treatment of AG490 in HeLa cells, we transfsect vector and CCDC7 respectively, 24 h later, the number of cells increased rapidly again (Figure 9A). Thus, these data suggested that CCDC7-dependent HeLa cell proliferation may involve the JAK pathway.
JAK-STAT3 activation has been reported to regulate the expression of a variety of important genes. Therefore, we next examined whether JAK-STAT3 was involved in cells transfected with CCDC7 or CCDC7 siRNA by measuring the phosphorylation of JAK and STAT3. JAK activation, as indicated by phosphorylation at the activation loop Tyr1007/1008 and STAT3 activation at the activation loop Tyr705. When transfected with CCDC7, P-JAK and P-STAT3 was increased, while P-JAK and P-STAT3 was reduced in cells transfected with CCDC7 siRNA as compared with control cells (Figure 9B).

Discussion
Cervical cancer is the third leading cause of cancer-related death in women worldwide, hence, a number of prognostic and predictive indicators are used to guide therapy in patients with cervical carcinoma. Previous studies have shown that cervical cancer, colon cancer, and endometrial cancer are associated with the mRNA expression of CCDC7 gene family. In this study, we analyzed the role and clinical significance of CCDC7 gene in cervical cancer. Our results demonstrated that CCDC7 expression was associated with the progression of cervical cancer and that CCDC7 regulated cell proliferation via the JAK-STAT3 pathway.
The expression levels of CCDC7, IL-6, and VEGF exhibited similar patterns in tumors from nude mice and in human cervical cancer samples.

**Figure 7 (A)** The expression levels of CCDC7, IL-6, and VEGF exhibited similar patterns in tumors from nude mice and in human cervical cancer samples. Immunohistochemical staining of CCDC7, IL-6, and VEGF (brown) in paraffin-embedded sections of nude mice’s tumors. Typical images were taken under a light microscope (magnification 400×). (B) Western blotting was used to analyze the expression of CCDC7, IL-6, VEGF, and PCNA in nude mice with HeLa cell-derived tumors. (C) Western blotting was used to analyze the expression of CCDC7, IL-6, and VEGF in human clinical cervical cancer samples, left: stage 1; right: stage 3. β-Actin was used as a loading control.
Figure 8 Expression of CCDC7, VEGF, and IL-6 was associated with tumor growth. (Upper) CCDC7, IL-6, and VEGF expression in normal cervical tissues and squamous carcinoma tissues. CCDC7 (left), IL-6 (middle), and VEGF (right) expression was investigated in the same three tissue microarrays of clinical cervical cancer samples. (Lower) The immunohistochemical staining score was analyzed using GraphPad Prism 5.0.
pathway and the expression of IL-6 and VEGF cytokines. These data provide important insights into the role of CCDC7 in cervical cancer.

The proliferative capacity of tumor cells plays an important role in the invasiveness and metastasis of specific cancers. In this study, we found that the expression of CCDC7 was closely associated with the proliferation of HeLa cervical cancer cells. Indeed, when we manipulated the expression of CCDC7 in HeLa cells, including in vitro and in vivo experiment, we observed that overexpression of CCDC7 promoted cell proliferation while knockdown of CCDC7 expression inhibited cell proliferation. In the model of cervical cancer in nude mice, we observed that knockdown of CCDC7 expression can therapy the mice tumor and inhibit tumor growth. Thus, CCDC7 was shown to be a potent oncogetic protein and a new therapeutic target in cervical cancer.

IL-6 is a pleiotropic inflammatory cytokine that induces the growth and differentiation of immune cells as well as the expression of many cytokines. IL-6 is also a representative marker of clinical correlation and a common prognostic factor in patients with cancer. Various studies have suggested that IL-6 is important in cervical carcinogenesis because it is a central pro-inflammatory cytokine involved in female genital infection and is abundant in the microenvironment of cervical cancer. Moreover, the association of IL-6 with angiogenesis has been reported to depend on its ability to induce the production of VEGF, a potent angiogenic agent. In gastric carcinoma, IL-6 induces VEGF expression by increasing angiogenesis and therefore may be a marker of tumor angiogenesis and disease status. Furthermore, recent studies have revealed that IL-6 and VEGF can increase tumor growth capacity and are targets for potential therapeutic interventions.
for the diagnosis, treatment, and prognosis of tumors. Consistent with this, in our study, we found that CCDC7 expression was positively correlated with IL-6 and VEGF expression; overexpression of CCDC7 upregulated IL-6 and VEGF, while knockdown of CCDC7 downregulated these two cytokines. Moreover, addition of recombinant IL-6 or VEGF also caused CCDC7 expression to increase. Consistent patterns of expression were also observed in tumors from nude mice and in clinical specimens of cervical cancer. Thus, our data demonstrated that these three molecules were interconnected in promoting the progression of cervical cancer. However, it is not clear whether these molecules interact directly; further studies are required to investigate these effects.

IL-6 has been reported to regulate the JAK/STAT, Ras/MAPK, and PI3K/Akt pathways. Inappropriate activation of JAK/STAT signaling occurs with high frequency in human cancers and is associated with cancer cell survival and proliferation. STAT3 regulates fundamental biological processes, including cell proliferation, survival, and development. Recently, accumulating evidence has indicated that abnormalities in the JAK/STAT signaling pathway are involved in the oncogenesis of several cancers. STAT proteins are transcription factors that participate in normal cellular events, such as proliferation, apoptosis, and angiogenesis, and STAT3 has been shown to be required in many aspects of tumorigenesis. In our study, we showed that specifically blocking the JAK/STAT pathway by AG490 could reduce HeLa cell proliferation, and this effect was abrogated by expression of CCDC7. Thus, these data confirmed that the effects of CCDC7 on HeLa cell proliferation were regulated though the JAK-STAT pathway. Moreover, as STAT3 phosphorylation and nuclear translocation are required for STAT3 transcriptional activity, we also analyzed the phosphorylation of JAK2 and STAT3 in HeLa cells overexpressing CCDC7. Importantly, overexpression CCDC7 promoted phosphorylation of these targets, while CCDC7 knockdown significantly suppressed phosphorylation of these targets, thereby supporting that CCDC7 was involved in activation of the JAK-STAT3 pathway.

Conclusion

In conclusion, we demonstrated, for the first time, that CCDC7 played an important role in the regulation of cervical cancer proliferation through modulation of IL-6 and VEGF expression. Interestingly, IL-6 and VEGF also mediated CCDC7 expression. In the model of cervical cancer in nude mice, the CCDC7-shRNA therapeutic experiments confirmed that the interference of endogenous CCDC7 could inhibit the cell proliferation and tumor growth, which had the effect of therapeutic of cervical cancer. These findings have clinical applications for the treatment and diagnosis of patients with cervical cancer and suggest that CCDC7 may be an important therapeutic target in cervical cancer. Additionally, CCDC7 was identified as an oncogenic protein in cervical cancer and maybe function via the JAK-STAT3 pathway. However, further research is still required to determine the precise mechanisms through which CCDC7 and IL-6/VEGF interact.

Abbreviations

CCDC7, coiled coil domain containing 7; IL, interleukin; VEGF, vascular endothelial growth factor; JAK, Janus kinase, STAT, signal transducer and activator of transcription; ELISA, enzyme-linked immunosorbent assay; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; qRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositol 3 kinase; MEK1/2, MAP kinase kinase; MTT, 3-(4,5-dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide; DAB, diaminobenzidine; DMSO, dimethylsulfoxide; HRP, horseradish peroxidase; ANOVA, analysis of variance.

Ethical Statement

All animal experiments were carried out in accordance with the regulations of the People’s Republic of China on the administration of experimental animals and performed according to protocols approved by the Animal Care and Use Committee of Sichuan University. The experiments on humans or human tissues were undertaken with the understanding and written informed consent from the patient donors. The study methodologies were approved by the Sichuan University ethics committee.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (81102062), Sichuan Youth Science and Technology Foundation (2016JQ0060), Sichuan Applied Basic Research Project (2017JY0299), and the CSCO-Merck Serono Cancer Research Fund (Y-MT2016-009).
Disclosure
We certify that regarding this paper, no actual or potential conflicts of interests exist; the authors declare that they have no conflicts of interest associated with the publication of the present work.

References
1. Dursun P, Caglar M, Akilli H, et al. Large conization and laparoscopic single-port pelvic lymphadenectomy in early-stage cervical cancer for fertility preservation. Case Rep Surg. 2013;207191.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–543. doi:10.1016/S1470-2045(01)00486-7
3. He L, Wu L, Su G, et al. The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer. Gynecol Oncol. 2014;134(2):419–425. doi:10.1016/j.ygyno.2014.06.001
4. Wang H, Zhang P, Wang CT. Analysis of expression pattern of a novel testis-highly expressed gene Biot2-L and the primary study on its role in testis development. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40(5):853–856.
5. Yangmei S, Xiang H, Hongxin D, et al. Expression of human Biot2 and its potential function on carcinogenesis in endometrial cancer. Acta Obstet Gynecol Scand. 2007;86(12):1503–1509. doi:10.1080/00016340701736946
6. Shen YM, He X, Deng HX, et al. Overexpression of the hBiot2 gene is associated with development of human cervical cancer. Oncol Rep. 2011;25:75–80.
7. Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275
8. Shen YM, Arbman G, Sandstrom P, et al. Novel gene hBiot2 is an independent prognostic factor in colorectal cancer patients. Oncol Rep. 2012;27(2):376–382. doi:10.3892/or.2011.1521
9. Taniguchi K, Karin M. IL-6 and related cytokines as the critical cytokines links between inflammation and cancer. Semin Immunol. 2014;26(1):54–74. doi:10.1016/j.smim.2014.01.001
10. Migita K, Izumi Y, Torigoshi T, et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol. 2013;174(3):356–363. doi:10.1111/cei.12190
11. Vargas-Hernández A, Forbes LR. JAK/STAT proteins and their biological impact on NK cell development and function. Mol Immunol. 2019;115:21–30. doi:10.1016/j.molimm.2018.12.005
12. Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAK. STAT. 2014;3:e28086. doi:10.4161/jkst.28086
13. Wu CJ, Sundararajan V, Shue BC, et al. Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: mechanism and therapeutic opportunity. Cancers (Basel). 2019;12:1. doi:10.3390/cancers12010024
14. Jarnicki A, Putocki Z, Ernst M. STAT3: linking inflammation to epithelial cancer more than a “gut” feeling? Cell Div. 2010;5(1):14. doi:10.1186/1747-1028-5-14
15. Tang Y, Tian XC. JAK-STAT3 and somatic cell reprogramming. JAK STAT. 2013;2:e24935.
16. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAK STAT. 2013;2:e23828.
17. Munoz J, Dhillon N, Janku F, et al. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014;19(5):536–544. doi:10.1634/theoncologist.2013-0407
18. Xiong A, Yang Z, Shen Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel). 2014;6:926–957. doi:10.3390/cancers602262
19. Wen Y, Wang C-T, Tian-Tai M, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010;101(11):2325–2332. doi:10.1111/j.1349-7006.2010.01695.x
20. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22(10):1517–1527. doi:10.1038/sj.onc.1206226
21. Sun B, Kawahara M, Ehata S, et al. AAG8 promotes carcinogenesis by activating STAT3. Cell Signal. 2014;26(9):1863–1869. doi:10.1016/j.cellsig.2014.04.001
22. Chowdhury SR, Saleh A, Akude E, et al. Ciliary neurotrophic factor reverses aberrant mitochondrial bioenergetics through the JAK/STAT pathway in cultured sensory neurons derived from streptozotocin-induced diabetic rodents. Cell Mol Neurobiol. 2014;34(5):643–649. doi:10.1007/s10571-014-0054-9
23. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine. 2006;3:S3:71–77.
24. Dar AA, Nosrati M, Bezzrookove V, et al. The Role of BPTF in melanoma progression and in response to braf-targeted therapy. J Natl Cancer Inst. 2015;107(5):5. doi:10.1093/jnci/djv034
25. Mirkeshavarz M, Ganjbakhsh M, Aminishakib P, et al. Interleukin-6 secreted by oral cancer-associated fibroblast accelerated VEGF expression in tumor and stroma cells. Cell Mol Biol (Noisy-Le-Grand). 2017;63(10):131–136.
26. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–139. doi:10.1016/j.pharmthera.2013.09.004
27. Wang Z, Si X, Xu A, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS One. 2013;8(10):e75788. doi:10.1371/journal.pone.0075788
28. Huang SP, Wu MS, Shun CT, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci. 2004;11(4):517–527. doi:10.1007/BF02256101
29. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223–1231.
30. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734
31. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016;138(11):2570–2578. doi:10.1002/ijc.29923